Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL

Publication
Video
Supplements and Featured PublicationsYear in Review: Updates in DLBCL Treatment
Volume 1
Issue 1

In Partnership With:

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

Kami J. Maddocks, MD, an associate professor of clinical internal medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center–James, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma (DLBCL).

As more therapies are approved for the treatment of patients with DLBCL, sequencing challenges continue to arise, Maddocks explains.

For example, the question of whether CAR T-cell therapies can be moved into earlier lines of treatment for patients with high-risk disease or who are not candidates for autologous stem cell transplant remains unanswered, Maddocks says.

Additionally, the recently approved CD19-directed monoclonal antibody tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid), as well as other CD19-directed therapies under investigation, may have efficacy earlier on in treatment or for patients who progress after CAR T-cell therapy, says Maddocks.

Other therapies such as polatuzumab vedotin (Polivy) in combination with bendamustine and rituximab (Rituxan; BR) and selinexor (Xpovio) are currently approved for the treatment of patients who have received at least 2 prior therapies. However, the optimal role of these agents has yet to be determined, concludes Maddocks.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD